Literature DB >> 23131610

The pathogenesis of systemic lupus erythematosus-an update.

Jinyoung Choi1, Sang Taek Kim, Joe Craft.   

Abstract

Systemic lupus erythematosus (SLE, lupus) is characterized by a global loss of self-tolerance with activation of autoreactive T and B cells leading to production of pathogenic autoantibodies and tissue injury. Innate immune mechanisms are necessary for the aberrant adaptive immune responses in SLE. Recent advances in basic and clinical biology have shed new light on disease mechanisms in lupus, with this review discussing the recent studies that offer valuable insights into disease-specific therapeutic targets.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23131610      PMCID: PMC3508331          DOI: 10.1016/j.coi.2012.10.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  81 in total

Review 1.  BAFF and selection of autoreactive B cells.

Authors:  Zheng Liu; Anne Davidson
Journal:  Trends Immunol       Date:  2011-07-13       Impact factor: 16.687

2.  Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.

Authors:  Eneida Villanueva; Srilakshmi Yalavarthi; Celine C Berthier; Jeffrey B Hodgin; Ritika Khandpur; Andrew M Lin; Cory J Rubin; Wenpu Zhao; Stephen H Olsen; Matthew Klinker; David Shealy; Michael F Denny; Joel Plumas; Laurence Chaperot; Matthias Kretzler; Allen T Bruce; Mariana J Kaplan
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

3.  The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.

Authors:  Laurence Menard; David Saadoun; Isabelle Isnardi; Yen-Shing Ng; Greta Meyers; Christopher Massad; Christina Price; Clara Abraham; Roja Motaghedi; Jane H Buckner; Peter K Gregersen; Eric Meffre
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors:  Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2011-12

Review 5.  Follicular helper CD4 T cells (TFH).

Authors:  Shane Crotty
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Authors:  Joan T Merrill; Daniel J Wallace; Michelle Petri; Kyriakos A Kirou; Yihong Yao; Wendy I White; Gabriel Robbie; Robert Levin; Seth M Berney; Vishala Chindalore; Nancy Olsen; Laura Richman; Chenxiong Le; Bahija Jallal; Barbara White
Journal:  Ann Rheum Dis       Date:  2011-07-27       Impact factor: 19.103

7.  An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.

Authors:  Anupama Ahuja; Lino L Teichmann; Haowei Wang; Robert Dunn; Marilyn R Kehry; Mark J Shlomchik
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

8.  Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus.

Authors:  Alexis Mathian; Zahir Amoura; Estelle Adam; Fabien Colaone; Marco F M Hoekman; Olivier Dhellin; Pierre Vandepapelière; Julien Haroche; Jean-Charles Piette; Pierre Lebon; Géraldine Grouard-Vogel
Journal:  Ann Rheum Dis       Date:  2011-03-09       Impact factor: 19.103

9.  In vivo regulation of Bcl6 and T follicular helper cell development.

Authors:  Amanda C Poholek; Kyle Hansen; Sairy G Hernandez; Danelle Eto; Anmol Chandele; Jason S Weinstein; Xuemei Dong; Jared M Odegard; Susan M Kaech; Alexander L Dent; Shane Crotty; Joe Craft
Journal:  J Immunol       Date:  2010-06-02       Impact factor: 5.422

Review 10.  Abnormalities of T cell signaling in systemic lupus erythematosus.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  Arthritis Res Ther       Date:  2011-03-17       Impact factor: 5.156

View more
  96 in total

Review 1.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.

Authors:  Bo Zheng; Xiang-Qing Yu; Warren Greth; Gabriel J Robbie
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

Review 3.  The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved.

Authors:  Ole Petter Rekvig; Johan Van der Vlag
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

4.  Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy.

Authors:  F Bonilla-Abadía; J F Betancurt; J C Pineda; J D Vélez; G J Tobón; C A Cañas
Journal:  Clin Rheumatol       Date:  2014-01-09       Impact factor: 2.980

Review 5.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

6.  Elevated semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Authors:  Y Du; X Wu; M Chen; W Wang; W Xv; L Ye; D Wu; J Xue; W Sun; J Luo; H Wu
Journal:  Clin Exp Immunol       Date:  2017-02-17       Impact factor: 4.330

Review 7.  Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: A B-cell immunomics approach.

Authors:  Christopher M Tipton; Jennifer R Hom; Christopher F Fucile; Alexander F Rosenberg; Inaki Sanz
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

Review 8.  Belimumab in systemic lupus erythematosus: a perspective review.

Authors:  Joyce S Hui-Yuen; Xiao Q Li; Anca D Askanase
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

9.  Down-regulation of nectin-4 inhibits apoptosis in systemic lupus erythematous (SLE) through targeting Bcl-2/Bax pathway.

Authors:  Weihua Zheng; Ying Wu; Wenyan Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease.

Authors:  Nunzio Bottini; Erik J Peterson
Journal:  Annu Rev Immunol       Date:  2013-12-18       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.